A PYMNTS Company

Mexico: COFECE puts the breaks on Sanofi-Boehringer merger

By  |  April 10, 2017

Cofece, Mexico’s antitrust commission, objected to the merger of the pharmaceutical companies Sanofi and Boehringer Ingelheim International in the animal health sector, considering that competition in five animal vaccine markets in Mexico would be at risk.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The agency said that the proposed merger consists of Boehringer acquiring the animal health business that Sanofi operates in Mexico, a transaction that is part of an international transaction agreed on by both companies.

    Cofece explained that in this merger, both companies agreed on the commercialization of various vaccines and medicines indicated for poultry, pigs, cattle, goats and sheep, and others.

    To ensure that competitive conditions will remain in all five markets, Cofece ruled that the transaction would only be authorized if the companies agreed to the divestment of four Boehringer and one Sanofi vaccine to a third party.

    Full Content: El Economista

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.